Maxim Group Maintains a Buy Rating on Joint Corp


Maxim Group analyst Anthony Vendetti maintained a Buy rating on Joint Corp (NASDAQ: JYNT) today and set a price target of $10. The company’s shares closed yesterday at $7.54, close to its 52-week high of $8.

Vendetti noted:

“1Q18 revenue of $7.10M, up 28.9% y/y, was relatively inline with both our estimate of $7.18M and consensus of $7.06M..”

Vendetti has an average return of 58.3% when recommending Joint Corp.

According to TipRanks.com, Vendetti is ranked #532 out of 4798 analysts.

Joint Corp has an analyst consensus of Moderate Buy, with a price target consensus of $8.88.

See today’s analyst top recommended stocks >>

Based on Joint Corp’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $213.2K. In comparison, last year the company had a GAAP net loss of $1.65 million.

Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

The Joint Corp. (United States) develops, owns, operates, supports and manages chiropractic clinics through direct ownership, management arrangements, franchising and the sale of regional developer rights throughout the United States.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts